To evaluate role of growth factors, mainly i-PRF in treatment of Temporomandibular disorders (TMD). 2. To compare effectiveness of i-PRF in pain reduction with conservative treatments patients were divided randomly into control and test (30 each group). Each underwent MRI and only after confirming disc related problem, treatment was started, control group was kept on conservative treatment, whereas in test group, injectable platelet rich plasma (iPRF) was injected in the joint space. The follow-up period of both the groups was 6 months. In test group (subjects who received iPRF injection) 30.4% showed VAS score 0 at day 15, and at 6 months about 78.3% of subjects show VAS score 0. In the control group, at day 15 for control group, 32% of the subjects showed VAS score 0, and at 6 months about 29% subjects show VAS score 0. Similarly, in the test group, pre-operatively there are 23.9% of participants in stage I (wilkes classification) category of TMJ pain and 17.4% in the stage V category, at the end of 6 months, this number was reduced to 0% in the stage V category and 82.6% in stage I category. iPRF works for the pain management of TMJ and has a long-lasting effect on the repair and regeneration of the disc and should be considered as the primary treatment modality for TMD.
Shukla et al. (Tue,) studied this question.